Last reviewed · How we verify
Acute pulmonary edema — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Lasix | furosemide | Generic (originally Hoechst AG) | Loop Diuretic [EPC] | ATP-binding cassette sub-family G member 2, CDGSH iron-sulfur domain-containing protein 1, G-protein coupled receptor 35 | 1966-07-01 | |
| Frusemide | Frusemide | Melbourne Health | ATP-binding cassette sub-family G member 2, CDGSH iron-sulfur domain-containing protein 1, G-protein coupled receptor 35 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Generic (originally Hoechst AG) · 1 drug in Acute pulmonary edema
- Melbourne Health · 1 drug in Acute pulmonary edema
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Acute pulmonary edema:
- Acute pulmonary edema treatment updates — RSS
- Acute pulmonary edema treatment updates — Atom
- Acute pulmonary edema treatment updates — JSON
Cite this brief
Drug Landscape (2026). Acute pulmonary edema — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/acute-pulmonary-edema. Accessed 2026-06-10.
Related
- Acute pulmonary edema full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing